Aerie Pharmaceuticals Inc Ret. on equity
What is the Ret. on equity of Aerie Pharmaceuticals Inc?
The Ret. on equity of Aerie Pharmaceuticals Inc is 32.63%
What is the definition of Ret. on equity?
Return on equity is a measure of the profitability of a business in relation to the book value of the shareholder equity. It is computed by dividing fiscal year net income by total shareholder equity.
ttm (trailing twelve months)
The return on equity (ROE) ROE is a measure of how well a company uses investments to generate earnings growth. ROE is used for comparing the performance of companies in the same industry. It indicated the management's ability to generate income from the equity available to it. ROEs of 15-20% are generally considered good. ROEs are also a factor in stock valuation, in association with other financial ratios. In general, stock prices are influenced by earnings per share (EPS), so that stock of a company with a 20% ROE will generally cost twice as much as one with a 10% ROE.
Ret. on equity of companies in the Health Care sector on NASDAQ compared to Aerie Pharmaceuticals Inc
What does Aerie Pharmaceuticals Inc do?
Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie's first product, Rhopressa® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie's second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema.
Companies with ret. on equity similar to Aerie Pharmaceuticals Inc
- Accenture plc has Ret. on equity of 32.59%
- Denbury has Ret. on equity of 32.60%
- Synalloy has Ret. on equity of 32.61%
- Check Point Software Technologies has Ret. on equity of 32.61%
- China Ceramics Co has Ret. on equity of 32.61%
- Southern Copper has Ret. on equity of 32.62%
- Aerie Pharmaceuticals Inc has Ret. on equity of 32.63%
- 1137943 has Ret. on equity of 32.64%
- Arena REIT has Ret. on equity of 32.65%
- Emcor has Ret. on equity of 32.67%
- Pzena Investment Management Inc has Ret. on equity of 32.68%
- Établissements Maurel & Prom SA has Ret. on equity of 32.71%
- Altisource Portfolio Solutions S.A has Ret. on equity of 32.72%